OpenAI Acquires Orchestra Bio for Drug Development AI
OpenAI acquires Orchestra Bio to enhance its AI model for life sciences research.
"OpenAI just bought Orchestra Bio to supercharge drug development with AI. Get ready for faster breakthroughs in biotech."
OpenAI has acquired Orchestra Bio, a startup focused on AI biotech software. The acquisition was reported by Axios and confirmed by OpenAI. Orchestra Bio's team and technology will be integrated into OpenAI's Rosalind, an AI model for life sciences research, and its related Rosalind Workbench tool.
Rosalind Workbench is designed to help researchers plan experiments and analyze results. Orchestra Bio creates AI agents that assist biotech companies with drug-discovery operations, including tracking finances and resolving scheduling issues in clinical trials. The startup had reportedly raised approximately $20 million as of 2025 from backers such as Andreessen Horowitz, Atria, and 8VC.
This acquisition aims to boost drug development AI capabilities within OpenAI. OpenAI has stated that Rosalind already serves customers like Moderna and Novo Nordisk. The move signifies how major AI labs are expanding their software offerings for large industries like pharmaceuticals.
This acquisition signals OpenAI's deeper entry into the biotech and pharmaceutical sectors, potentially accelerating drug discovery through advanced AI. Businesses in these industries should note the increasing integration of AI tools for operational efficiency and research. It highlights a trend of major AI labs expanding their direct offerings to established industries.
Relevant tools
Find the right AI tool for your business
Chat with Insta and get matched to the right tool in seconds.
Try Insta Tool Finder →